← Leaderboards
Dennis P Hughes
University Of Michigan At Ann Arbor
$3,404,194
Attributed
$3,404,194
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $789.3K · FY2006–14$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$3,404,194 · 4
By mechanism
R01$2,605,034 · 2
K08$688,500 · 1
F32$110,660 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Carol A Fierke$10,633,810
- Jesse C Hay$4,503,424
- James E. Penner-Hahn$9,154,844
- Shaomeng Wang$36,139,079
- Vernon K. Sondak$499,486
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineSignal TransductionXenograft ModelMalignant NeoplasmsIn VivoInhibitor/AntagonistFamilyApoptosisLaboratoriesBaseOsteosarcomaPhenotypePrognosticIn VitroImmunohistochemistrySamplingMalignant - DescriptorCessation Of LifeMalignant Breast NeoplasmDisease ModelBehaviorGenesAffectMalignant Bone Neoplasm
Grant awards (19)
Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling$318,015
R01 · FY2014 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$328,827
R01 · FY2013 · CA · contact PI
Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling$308,179
R01 · FY2013 · CA · contact PI
Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling$58,739
R01 · FY2013 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$58,739
R01 · FY2013 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$349,816
R01 · FY2012 · CA · contact PI
Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling$327,850
R01 · FY2012 · CA · contact PI
Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling$62,488
R01 · FY2012 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$49,145
R01 · FY2012 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$349,816
R01 · FY2011 · CA · contact PI
Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling$262,280
R01 · FY2011 · CA · contact PI
Ras-mediated erbB signaling in Osteosarcoma$137,700
K08 · FY2010 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$131,140
R01 · FY2010 · CA · contact PI
Ras-mediated erbB signaling in Osteosarcoma$137,700
K08 · FY2009 · CA · contact PI
Ras-mediated erbB signaling in Osteosarcoma$137,700
K08 · FY2008 · CA · contact PI
Ras-mediated erbB signaling in Osteosarcoma$137,700
K08 · FY2007 · CA · contact PI
Ras-mediated erbB signaling in Osteosarcoma$137,700
K08 · FY2006 · CA · contact PI
Genetic immunotherapy for malignancy: murine modeling$56,308
F32 · FY2003 · CA
Genetic immunotherapy for malignancy: murine modeling$54,352
F32 · FY2002 · CA